Literature DB >> 25239303

Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk?

Nadine M P Daan1, Yvonne V Louwers2, Maria P H Koster3, Marinus J C Eijkemans4, Yolanda B de Rijke5, Eef W G Lentjes6, Bart C J M Fauser3, Joop S E Laven2.   

Abstract

OBJECTIVE: To study the cardiometabolic profile characteristics and compare the prevalence of cardiovascular (CV) risk factors between women with different polycystic ovary syndrome (PCOS) phenotypes.
DESIGN: A cross-sectional multicenter study analyzing 2,288 well phenotyped women with PCOS.
SETTING: Specialized reproductive outpatient clinic. PATIENT(S): Women of reproductive age (18-45 years) diagnosed with PCOS. INTERVENTION(S): Women suspected of oligo- or anovulation underwent a standardized screening consisting of a systematic medical and reproductive history taking, anthropometric measurements, and transvaginal ultrasonography followed by an extensive endocrinologic/metabolic evaluation. MAIN OUTCOME MEASURE(S): Differences in cardiometabolic profile characteristics and CV risk factor prevalence between women with different PCOS phenotypes, i.e., obesity/overweight, hypertension, insulin resistance, dyslipidemia, and metabolic syndrome. RESULT(S): Women with hyperandrogenic PCOS (n=1,219; 53.3% of total) presented with a worse cardiometabolic profile and a higher prevalence of CV risk factors, such as obesity and overweight, insulin resistance, and metabolic syndrome, compared with women with nonhyperandrogenic PCOS. In women with nonhyperandrogenic PCOS overweight/obesity (28.5%) and dyslipidemia (low-density lipoprotein cholesterol≥3.0 mmol/L; 52.2%) were highly prevalent. CONCLUSION(S): Women with hyperandrogenic PCOS have a worse cardiometabolic profile and higher prevalence of CV risk factors compared with women with nonhyperandrogenic PCOS. However, all women with PCOS should be screened for the presence of CV risk factors, since the frequently found derangements at a young age imply an elevated risk for the development of CV disease later in life.
Copyright © 2014 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Polycystic ovary syndrome; cardiovascular risk

Mesh:

Year:  2014        PMID: 25239303     DOI: 10.1016/j.fertnstert.2014.08.001

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  49 in total

1.  Age at Onset of Metabolic Syndrome Among Women With and Without Polycystic Ovary Syndrome-Like Status.

Authors:  Qing Peng; Carrie A Karvonen-Gutierrez; John F Randolph; Bin Nan; Daniel McConnell; Siobán D Harlow
Journal:  J Clin Endocrinol Metab       Date:  2019-05-01       Impact factor: 5.958

2.  Genotype, B-vitamin status, and androgens affect spaceflight-induced ophthalmic changes.

Authors:  Sara R Zwart; Jesse F Gregory; Steven H Zeisel; Charles R Gibson; Thomas H Mader; Jason M Kinchen; Per M Ueland; Robert Ploutz-Snyder; Martina A Heer; Scott M Smith
Journal:  FASEB J       Date:  2015-08-27       Impact factor: 5.191

Review 3.  The Influence of Sex on Cardiac Physiology and Cardiovascular Diseases.

Authors:  Yu Zhang; Bin Liu; Ranzun Zhao; Saidan Zhang; Xi-Yong Yu; Yangxin Li
Journal:  J Cardiovasc Transl Res       Date:  2019-07-01       Impact factor: 4.132

4.  Response to "Reproductive Function Abnormalities and Bariatric Surgery: is a Matter of Time?"

Authors:  Jacob Christ; Tommaso Falcone
Journal:  Obes Surg       Date:  2019-01       Impact factor: 4.129

5.  Metabolic implications of menstrual cycle length in non-hyperandrogenic women with polycystic ovarian morphology.

Authors:  Miro Šimun Alebić; Nataša Stojanović; Dinka Pavičić Baldani; Lea Smirčić Duvnjak
Journal:  Endocrine       Date:  2016-08-03       Impact factor: 3.633

6.  Reproductive health, obesity, and cardiometabolic risk factors among Samoan women.

Authors:  H Maredia; N L Hawley; G Lambert-Messerlian; U Fidow; M S Reupena; T Naseri; S T McGarvey
Journal:  Am J Hum Biol       Date:  2018-04-16       Impact factor: 1.937

7.  Gestational Diabetes Mellitus and Metabolic Disorder Among the Different Phenotypes of Polycystic Ovary Syndrome.

Authors:  Mahnaz Ashrafi; Fatemeh Sheikhan; Arezoo Arabipoor; Nicole Rouhana; Roya Hosseini; Zahra Zolfaghari
Journal:  Oman Med J       Date:  2017-05

Review 8.  Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review.

Authors:  Leslie Cho; Melinda Davis; Islam Elgendy; Kelly Epps; Kathryn J Lindley; Puja K Mehta; Erin D Michos; Margo Minissian; Carl Pepine; Viola Vaccarino; Annabelle Santos Volgman
Journal:  J Am Coll Cardiol       Date:  2020-05-26       Impact factor: 24.094

9.  Hyperinsulinemia and obese phenotype differently influence blood pressure in young normotensive patients with polycystic ovary syndrome.

Authors:  Roberto Mioni; Anna Dalla Cà; Jenni Turra; Sara Azzolini; Nadia Xamin; Luigi Bleve; Pietro Maffei; Roberto Vettor; Francesco Fallo
Journal:  Endocrine       Date:  2016-05-03       Impact factor: 3.633

10.  Lifestyle changes in women with polycystic ovary syndrome.

Authors:  Siew S Lim; Samantha K Hutchison; Emer Van Ryswyk; Robert J Norman; Helena J Teede; Lisa J Moran
Journal:  Cochrane Database Syst Rev       Date:  2019-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.